|Bid||70.20 x 1300|
|Ask||0.00 x 1300|
|Day's Range||94.56 - 95.29|
|52 Week Range||77.00 - 96.57|
|Beta (3Y Monthly)||0.67|
|PE Ratio (TTM)||32.39|
|Earnings Date||Feb 13, 2019 - Feb 18, 2019|
|Forward Dividend & Yield||0.66 (0.70%)|
|1y Target Est||100.09|
In his second "Executive Decision" segment of Mad Money Friday night, Jim Cramer sat down with Juan Ramon Alaix, CEO of Zoetis Inc. ZTS is an animal health company with shares that vaulted 9.8% last week after another strong quarter. Alaix added that Zoetis has effective treatments for a number of conditions, including ticks, fleas, heartworm and other parasites.
Announcement: Moody's announces completion of a periodic review of ratings of Zoetis Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Zoetis Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Shares of animal health outlet Zoetis popped Thursday after Zoetis earnings and sales easily topped fourth-quarter expectations. Zoetis stock is approaching a potential buy point.
The company, the largest publicly traded animal-health business, earned more than expected and issued an encouraging forecast for the current year.
Zoetis (ZTS) delivered earnings and revenue surprises of 2.60% and 3.14%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Parsippany, New Jersey-based company said it had profit of 71 cents. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, came to 79 cents ...
On Thursday, Feb. 14, Zoetis (NYSE: ZTS ) will release its latest earnings report. Benzinga's outlook for Zoetis is included in the following report. Earnings and Revenue Zoetis EPS is expected to be around ...
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future use of cash and dividend payments, and other future events.
Zoetis Inc. (ZTS) is gearing up to report fourth-quarter 2018 results. The company continues to strengthen its diverse product portfolio through lifecycle innovations, strong customer relationships, and access to new markets and technologies.
The drug giant announced on Friday that it will unload the remaining shares it holds of Elanco Animal Health through a voluntary stock-exchange offer.
Zoetis Inc NYSE:ZTSView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ZTS with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZTS. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ZTS totaled $14.89 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples Read More...
NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zoetis Inc. will host a webcast and conference call at 8:30 a.m. on Thursday, Feb. 14, 2019. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review fourth quarter and full year 2018 financial results and respond to questions from financial analysts during the call.
Jim Cramer sits down with Zoetis CEO Juan Ramos Alaix to discuss how parents pay for their pets' health care and a future product launch.